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ABSTRACT
Background and Objectives: The aim of this study was to examine the anti-proliferative and anti-inflammatory effects of a 
stent coated with abciximab and alpha-lipoic acid (ALA) in a porcine coronary overstretch restenosis model. Materials and 
Methods: A total of 10 pigs were randomized into two groups (10 pigs, 10 coronaries in each group) in which the coronary 
arteries were stented with a dual-coated stent and a bare metal stent (control) by randomization. Stents were deployed with 
oversizing (stent/artery ratio 1.3 : 1) in the porcine coronary arteries, and histopathology was assessed 28 days after stenting. 
Results: There was no significant difference in the injury score between the two groups. In the neointima, the lymphohistio-
cyte count was significantly lower in dual-coat stent group compared with the control stent group (120±85 cells vs. 159±80 
cells, p=0.048). There was no significant difference in the fibrin score between the two groups (0.16±0.34 in the dual-coated 
stent group vs. 0.25±0.48 in the control stent group, p=0.446). The neointima area was not significantly different between 
both groups (1.55±0.8 mm
2 in dual-coated stent group vs. 1.40±0.86 mm
2 in the control stent group, p=0.447). Conclusion: 
Although the dual-coated stent with abciximab and ALA showed no significant difference in inhibition of neointimal hyper-
plasia when compared with the bare metal stent, it was associated with a reduced inflammatory reaction when compared 
with the control stent in a porcine coronary restenosis model. (Korean Circ J 2011;41:241-247)
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Introduction
The use of coronary stents has increased significantly in re-
cent years;
1) however, in-stent restenosis (ISR) after stent im-
plantation is major adverse effect.
2-4) The principal mechanism 
of ISR is thrombosis and neointimal hyperplasia, and it has 
been reported that there is a strong correlation between the 
degree of vascular inflammation and neointimal formation.
5-9) 
The pathological process of ISR is characterized by an inflam-
matory healing process after stretch and damage of the ves-
sel wall.
10)
Abciximab (Reopro
®) is a potent anti-platelet agent. Syste-
mic use of abciximab has significantly reduced thrombotic 
complications following complex angioplasty and stenting.
11-14) 
Alpha lipoic acid (ALA) is a potent antioxidant and acts as a co-
factor of key mitochondrial enzymes such as pyruvate dehy-
drogenase and α-ketoglutarate dehydrogenase.
15) ALA is be-
neficial for improving endothelial function and preventing 
atherosclerosis-related disease.
16) 
Therefore, in this study, we compared the effect of a stent 
coated with abciximab and ALA with that of bare metal stent 242   Dual Drug-Coated Stent With Abciximab and Alpha-Lipoic Acid
in a porcine coronary overstretch restenosis model.
Materials and Methods
Animals 
The animal study was approved by the Ethics Committee 
of Chonnam National University Medical School and Chon-
nam National University Hospital (CNU IACUC-H-2010-1), 
and conformed to the Guide for the Care and Use of Labo-
ratory Animals published by the US National Institutes of He-
alth (NIH Publication No. 85-23, revised 1996). Study animals 
were female swine weighing 25-35 kg.
Preparation of the dual-coated stent 
The dual-coated stent was prepared by grafting abciximab 
and ALA to a bare metal stent (3.0×18 mm, MAC
®stent, 
AMG, Munich, Germany) which had been coated with a poly-
mer layer by plasma polymerization of 1,2-diaminocyclohex-
ane (DACH) using the method of Song et al.
17)(Fig. 1).
Procedure
To prevent acute thrombosis after stenting, premedication 
with aspirin (100 mg/day) and clopidogrel (75 day/mg) was 
given for 7 days before the procedure. 
On the procedure day, pigs were anesthetized with ketamine 
{20 mg/kg intramuscularly (IM)} and xylazine (2 mg/kg IM). 
They received IM ketamine every 30 minutes and supplemen-
tal oxygen continuously through an oxygen mask. Subcutane-
ous 2% lidocaine was administered at the cut-down site, left 
carotid artery was surgically exposed, and a 7 French sheath was 
inserted. 
Continuous hemodynamic monitoring and surface electro-
cardiographic monitoring were maintained throughout the 
procedure. Heparin (5,000 units) was administered intraveno-
usly as a bolus prior to the procedure, the target coronary ar-
tery was engaged using standard 7 F guide catheters and con-
trol angiograms of both coronary arteries were performed us-
ing a nonionic contrast agent in two orthogonal views. 
The pigs were randomized into two groups with 10 corona-
ries per group. One group received the control bare metal st-
ents (3.0 ×18 mm, MAC
®stent, AMG, Munich, Germany) and 
the second group received dual-coated stents (3.0×18 mm, 
abciximab and ALA coated MAC
®stent). The stents were im-
planted in the proximal left anterior descending artery and 
proximal left circumflex artery and were deployed by inflating 
the balloon. The resulting stent-to-artery ratio was 1.3 : 1. Co-
ronary angiograms were obtained immediately after stent im-
plantation. All equipment was then removed and the carotid 
artery was ligated. All pigs continued to receive 100 mg of as-
pirin and 75 mg of clopidogrel daily until death.
Four weeks after stenting, the animals underwent follow-up 
angiography in the same orthogonal views. They were then 
sacrificed with an intercoronary injection of 20 mL of potassi-
um chloride. The hearts were removed and the coronary ar-
teries were pressure-perfusion fixed at 110 mmHg in 10% neu-
tral buffered formalin overnight. The arteries were step-sec-
tioned, processed routinely for light microscopy, and stained 
for histological analysis.
Histopathological analysis
Histopathologic evaluation of each artery was performed 
by an experienced cardiovascular pathologist. The specimens 
were embedded in methylmethacrylate and sections were cut 
with a low-speed diamond wafer mounted to a Buehler Isom-
et saw (Buehler Ltd., Lake Bluff, IL, USA), leaving the stent 
wires intact in the cross sections to minimize potential arti-
facts caused by removal of the stent wires. Sections of 50 to 100 
µm thickness were obtained at about 1 mm apart and stained 
with hematoxylin-eosin for histological analysis (Fig. 2). Mea-
surements of the histopathologic sections were performed us-
ing a calibrated microscope, digital video imaging system, and 
microcomputer program (Visus 2000 Visual Image Analysis 
System, IMT Tech, CA, USA). Borders were manually traced 
for the lumen area, the area circumscribed by the internal ela-
stic lamina, and the innermost border of the external elastic 
lamina (external elastic lamina area). Morphometric analysis 
of the neointimal area for a given vessel was calculated as the 
measured internal elastic lamina area minus the lumen area. 
Measurements were made on five cross-sections from the pro-
ximal and distal ends and the three midpoints of each stented 
segment. Histopathologic stenosis was calculated as 100×{1- 
(lesion lumen area/lesion internal elastic lamina area)}.
Evaluation of arterial injury
Arterial injury at each strut site was determined by the ana-
tomic structures penetrated by each strut. A numeric value 
was assigned, as previously described by Schwartz et al.
18) 
where 0=no injury, 1=break in the internal elastic membrane, 
2=perforation of the media, and 3=perforation of the external 
elastic membrane to the adventitia. The average injury score 
Fig. 1. Concentration of released ALA and abciximab in the release 
medium from an ALA-abciximab-grafted stent as a function of time. 
ALA: alpha lipoic acid.
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for each segment was calculated by dividing the sum of injury 
scores by the total number of struts at the examined section.
Evaluation of inflammation scores, neointimal 
reaction, and fibrin score
The inflammation score for each individual strut was grad-
ed as follows: 0=no inflammatory cells surrounding the strut; 
1=light, noncircumferential lymphohistiocytic infiltrate sur-
rounding strut; 2=localized, moderate to dense cellular aggre-
gate surrounding the strut noncircumferentially; and 3=cir-
cumferential dense lymphohistiocytic cell infiltration of the 
strut. The inflammation score for each cross section was cal-
culated by dividing the sum of the individual inflammation 
scores by the total number of struts at the examined section.
19) 
Inflammatory cell counts were normalized to neointimal hy-
perplasia area and percent area stenosis was compared be-
tween the two stent groups. Ordinal data for fibrin were col-
lected on each stent section using a scale of 0 to 3 as previous-
ly reported (Fig. 3).
20)
 
Statistical analysis
Statistical analysis was performed with the aid of the comme-
rcially available software (Statistical Package for the Social 
Sciences Version 15, Chicago, IL, USA). The data are present-
ed as mean value±SD. Unpaired Student’s t-test was used for 
the comparison of inflammatory cell counts normalized to in-
jury score of the two stent groups. Analysis of variance was 
used for comparisons of the two stent groups. To examine the 
correlations between the measured histologic variables, re-
gression analysis was applied for each set of measured variables. 
A p<0.05 was considered statistically significant.
Results
Ten pigs were used in this study (10 pigs, 10 coronaries in 
each group). A bare metal stent (control) and a dual coated stent 
were implanted in proximal left anterior descending artery and 
proximal left circumflex artery by randomized in a pig.
Mortality for this study was zero. Quantitative coronary an-
giographies before and after stent implantation established 
the stent-to-artery diameter ratio as 1.33±0.06 for all 20 st-
ented arteries. There was no significant difference in stent-to-
artery ratio among the two stent groups.
On histopathologic analysis, various amounts of inflamma-
tory cells and fibrin infiltrate surrounding on each strut sec-
tion. In the neointima, most of the inflammatory cells in both 
A  
C  
B  
D  
Fig. 2. Dual-coated stented porcine coronary arteries (A: H&E staining: ×20, B: methyl methacrylate staining: ×20) and control stented porcine 
coronary arteries (C: H&E staining: ×20, C: methyl methacrylate staining: ×20).244   Dual Drug-Coated Stent With Abciximab and Alpha-Lipoic Acid
groups were lymphohistiocytes. In contrast, eosinophils and 
plasma cells were not prominent. Carstair’s fibrin stain for de-
termining delayed arterial healing according to the discrimi-
nate fibrin score showed no difference between the two stent 
groups.
Significant correlations were found between the lymphohis-
tiocyte count and the neointimal hyperplasia area (r=0.567, 
p<0.001) and between the lymphohitiocyte count and the per-
cent area stenosis (r=0.476, p<0.001) (Fig. 4). There was no sig-
nificant difference in the injury score between the two groups 
(1.44±0.59 in the dual-coated stent group vs. 1.33±0.66 in the 
control stent group, p=0.522), nor in the neointima area 
(1.55±0.82 mm
2 in the dual-coated stent group vs. 1.40±0.86 
mm
2 in the control stent group, p=0.447) (Table 1). In the 
neointima, the lymphohistiocyte count was significantly lo-
wer in the dual-coated stent group compared with the control 
A  
C  
B  
D  
Fig. 3. The Carstair fibrin stain of the low- and high-power fields (magnitude, ×20, ×400) of fibrin infiltration in dual coating stent (A and B) and con-
trol stent (C and D).
Fig. 4. Correlations between the lymphohistiocyte count and neointimal hyperplasia area (A) and percent area stenosis (B).
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stent group (120±85 cells vs. 159±80 cells, p=0.048) (Fig. 5). 
There was no significant difference in the fibrin score between 
the two groups (0.16±0.34 in dual-coated stent group vs. 
0.25±0.48 in the control stent group, p=0.446) (Fig. 3). 
Discussion
In our study, dual coating of a bare metal stent with abcix-
imab and ALA by plasma polymerization of 1,2-DACH de-
monstrated no satisfactory inhibition of neointimal hyper-
plasia, but significantly lowered lymphohistiocyte counts com-
pared with bare metal control stents. 
Other studies have evaluated the effects of abciximab. In 
the EPIC trial, the incidence of further coronary events and 
the need for revascularization was reduced at 6 months post-
stenting and beyond.
13) Data from the EPISTENT trial also 
suggested a beneficial effect for abciximab on restenosis, al-
though this was limited to patients with diabetes.
21)
Other studies have shown that abciximab-coated stents 
reduce neointimal hyperplasia by inhibition of neointimal cell 
proliferation and extracellular matrix synthesis when com-
pared with bare-metal stents in a porcine coronary restenosis 
model.
22-24) Finally, two additional studies have reported that 
an abciximab-coated stent was feasible and produced signifi-
cant inhibition of neointimal hyperplasia, showing a potential 
therapeutic benefit in the prevention of stent restenosis in hu-
man trials.
25)26)
The results of the study presented here suggest that the pos-
sible mechanisms responsible for inhibition of neointimal hy-
perplasia by abciximab might be anti-platelet, anti-inflamma-
tory, and anti-proliferative actions.
ALA exists endogenously and improves diabetic-induced en-
dothelial dysfunction, probably due to antioxidant effects and 
direct free-radical scavenging properties.
27) Moreover, ALA in-
hibits the inflammatory pathway and prevents neointimal hy-
perplasia after stenting in the carotid artery.
28) Lim et al.
29) have 
shown that an ALA-coated stent inhibits neointimal forma-
tion in a porcine coronary restenosis model. On histopatho-
logic analysis, the neointimal area and the histopathologic 
area of stenosis were reduced in the ALA coated stent group 
compared with the control stent group. They hypothezied that 
by combining ALA and abciximab on a dual-coated stent, they 
could decrease the level of restenosis in the stented artery bas-
ed on the anti-proliferative effects of ALA and anticoagula-
tive effects of abciximab.
29) Aditionally, delivery of these agents 
by loading them onto the stent might allow site-specific deli-
very of an appropriate dose over a prolonged period, thereby 
reducing potential unwanted systemic effects.
The most important mechanism of coronary stent reste-
nosis is neointimal hyperplasia. However, the mechanism of 
the pathogenesis of neointimal hyperplasia is not well known. 
Previous studies have established that inflammation is a ma-
Table 1. Coronary artery morphometric measurements in stent ves-
sels in twenty stented vessel
Variables
Dual-coated stent
(n=10)
Control
(n=10)
p
Injury score 1.44±0.59 1.33±0.66 NS
Lymphohistiocyte 120±850 159±800 0.048
Fibrin score 0.16±0.34 0.25±0.48 NS
Neointima area (mm
2) 1.55±0.82 1.40±0.86 NS
NS: not significant
Fig. 5. (A) Injury score, (B) fibrin score, (C) neointima area, and (D) lymphohistiocyte count in control stent group compared with dual-coated 
stent group. NS: not significant.
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jor contributor to restenosis after stenting and a significant 
correlation has been found between the inflammatory reac-
tion and neointimal formation.
30) By contrast in our study, a 
decrease in neointimal hyperplasia was not seen, in spite of 
the decreased inflammatory reaction seen in the group re-
ceiving the dual-coated stent when compared with the control 
group. We hypothesize that there are other, as yet unknown 
factors effecting neointimal hyperplasia as well as additional 
known factors on which the combination of abcixumab and 
ALA would have no effect. One of these known reasons is an 
increase in extracellular matrix, which is known to play an im-
portant role in neointimal hyperplasia after coronary artery 
stenting.
30) 
Based on this data, we conclude that ALA and abciximab 
suppressed the inflammatory reaction, but did not suppress 
the other causes of neointimal hyperplasia such as the increase 
in theextracellular matrix. In contrast to preclinical studies on 
abciximab and ALA, our study demonstrated that a stent co-
ated with abciximab and ALA by plasma polymerization sh-
owed no satisfactory inhibition of neointimal hyperplasia 
compared with control stents in a porcine coronary restenosis 
model. We suspect that while the rapid release of abciximab 
and ALA suppressed the inflammatory reaction, the dosage 
of abciximab and ALA on the stent was not sufficient to in-
hibit neointimal hyperplasia. 
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